Insempra secures $20M Series A to advance bio-based alternatives in manufacturing

German biotech Insempra has successfully completed a $20 million Series A financing round.

Insempra enables businesses to transform their ingredient lists away from harmful chemicals and pollutants to superior natural ingredients at an industrial scale.

 The company creates naturally superior products to drive the regenerative revolution by harnessing new technologies to advance biological manufacturing processes. Insempra designs and builds these ingredients with atomic precision to rapidly produce and manufacture them at scale, offering better solutions to agriculturally and petrochemically sourced oils and materials.

Driven by market need and collaborations with world-wide renowned consumer brands, Insempra is growing lipids for cosmetic and food applications. 

It is also developing technology that offers a bio-based alternative to everyday materials such as polymers and textiles and progressing its biological solutions to create new natural molecules for use in functional ingredients, such as antioxidants and preservatives and flavours and fragrances.

Jens Klein, founder and CEO of Insempra, commented: 

“We are grateful for the support of this group of investors who have recognised the potential of Insempra’s market-first approach and innovative technology platforms.

Working in collaboration with nature, we will continue to expand our capacity to develop intrinsically sustainable materials that are superior in quality and will reduce our dependence on chemical industrialisation processes.”

Existing investors EQT Ventures, BlueYard Capital, Possible Ventures, Taavet Sten and Acequia Capital participated in the round. New investors are the corporate venture of international FMCG giant Henkel, Henkel dx Ventures, Bayern Kapital and Alante Capital.

Ted Persson, Partner at EQT Ventures, added:

“Insempra has both the team and the technology to drive a revolution in industrial manufacturing and gain rapid market traction for its products. New technology platforms such as Insempra’s have the potential to dramatically change the manufacturing processes of multiple multibillion-dollar industries, developing customised ingredients to fit market needs.”

Following an initial $15 million Seed round conducted in 2021, this financing round will support  Insempra in the scaleup of its technology, scouting, development, and manufacturing capabilities.

Lead image: Insempra. Photo: uncredited.